Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

First use of alemtuzumab in Balo's concentric sclerosis: a case report.
CD137 ligand activated microglia induces oligodendrocyte apoptosis via reactive oxygen species.
A phase II study of laquinimod in Crohn's disease.
Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis.
UW-SES: A new self-efficacy scale for people with disabilities.
Mechanism for p38α-mediated experimental autoimmune encephalomyelitis.
Magnetic Resonance Imaging of Optic Neuritis in Patients With Neuromyelitis Optica Versus Multiple Sclerosis.
Effects of functional electrical stimulation on gait function and quality of life for people with multiple sclerosis taking dalfampridine.
Effect of Genzyme’s LEMTRADA™ maintained in patients beyond two-year pivotal MS studies
Glossopharyngeal neuralgia secondary to vascular compression in a patient with multiple sclerosis: a case report.
Vivitrol dosing and administration
Sera from remitting and secondary progressive multiple sclerosis patients disrupt the blood-brain barrier.
Improvement of internuclear ophthalmoparesis in multiple sclerosis with dalfampridine.
Reduced serum orexin-A levels in autoimmune encephalitis and neuromyelitis optica patients.
Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease.
Helminth therapy and multiple sclerosis.
Cytotoxic NKG2C+ CD4 T Cells Target Oligodendrocytes in Multiple Sclerosis.
Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study.
Vitamin D3 Receptor ( VDR ) Gene rs2228570 (Fok1) and rs731236 (Taq1) Variants Are Not Associated with the Risk for Multiple Sclerosis: Results of a New Study and a Meta-Analysis.
A telerehabilitation program by virtual reality-video games improves balance and postural control in multiple sclerosis patients.
Laquinimod reduces neuroaxonal injury through inhibiting microglial activation.
First reported case of diabetes mellitus type 1 as a possible secondary autoimmune disease following alemtuzumab treatment in MS.
A guide to facilitate the early treatment of patients with idiopathic demyelinating disease (multiple sclerosis and neuromyelitis optica).
Associations of CD6, TNFRSF1A, and IRF8 polymorphisms with risk of inflammatory demyelinating diseases.
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients (TERI-PRO)

Pages